Sotorasib is a synthetic compound used as an active pharmaceutical ingredient. It acts as an inhibitor of the RAS GTPase family and is investigated for its role in targeting the G12C mutation in the KRAS protein associated with certain cancers.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 2296729-00-3
Sotorasib
pharmaceutical raw material
15-oxoprostaglandin E1
pharmaceutical raw material
Riociguat metabolite M3
pharmaceutical raw material
Atazanavir sulfate
pharmaceutical raw material
Terbutaline
pharmaceutical raw material
6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-yl-3-pyridinyl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one
NXQKSXLFSAEQCZ-SFHVURJKSA-N
C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C